Roger S Fine Net Worth

The estimated Net Worth of Roger S Fine is at least $36.7 Million dollars as of 31 August 2004. Roger Fine owns over 60,000 units of Johnson & Johnson stock worth over $36,742,663 and over the last 21 years Roger sold JNJ stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Roger Fine JNJ stock SEC Form 4 insiders trading

Roger has made over 2 trades of the Johnson & Johnson stock since 2004, according to the Form 4 filled with the SEC. Most recently Roger exercised 60,000 units of JNJ stock worth $804,600 on 31 August 2004.

The largest trade Roger's ever made was exercising 60,000 units of Johnson & Johnson stock on 31 August 2004 worth over $804,600. On average, Roger trades about 10,400 units every 29 days since 2003. As of 31 August 2004 Roger still owns at least 222,926 units of Johnson & Johnson stock.

You can see the complete history of Roger Fine stock trades at the bottom of the page.

What's Roger Fine's mailing address?

Roger's mailing address filed with the SEC is , , , , .

Insiders trading at Johnson & Johnson

Over the last 22 years, insiders at Johnson & Johnson have traded over $59,929,946 worth of Johnson & Johnson stock and bought 21,998 units worth $2,578,685 . The most active insiders traders include Hubert Joly, Anne M Mulcahy, and Alex Gorsky. On average, Johnson & Johnson executives and independent directors trade stock every 21 days with the average trade being worth of $4,572,436. The most recent stock trade was executed by Robert J Decker on 30 August 2024, trading 5,635 units of JNJ stock currently worth $563,838.

What does Johnson & Johnson do?

Johnson & Johnson is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods.

Complete history of Roger Fine stock trades at Johnson & Johnson

Johnson & Johnson executives and stock owners

Johnson & Johnson executives and other stock owners filed with the SEC include:

• Alex Gorsky,
  Chairman of the Board, Chief Executive Officer
• Paulus Stoffels,
  Vice Chairman- Executive Committee, Chief Scientific Officer
• Joaquin Duato,
  Vice Chairman - Executive Committee
• Joseph Wolk,
  Chief Financial Officer, Executive Vice President
• Jennifer Taubert,
  Executive Vice President - Worldwide Chairman, Pharmaceuticals
• Michael Ullmann,
  Executive Vice President, General Counsel
• Alex Gorsky,
  Exec. Chairman
• Peter Fasolo,
  Chief Human Resource Officer, Executive Vice President
• Dr. Paulus A. Stoffels M.D., Ph.D.,
  Chief Scientific Officer
• Joaquin Duato,
  CEO & Director
• Joseph J. Wolk CPA,
  Exec. VP & CFO
• Joseph J. Wolk C.P.A.,
  Exec. VP & CFO
• Jennifer L. Taubert,
  Exec. VP & Worldwide Chairman of Pharmaceuticals
• Anne Mulcahy,
  Lead Independent Director
• Charles Prince,
  Independent Director
• Mary Beckerle,
  Independent Director
• Ronald Williams,
  Independent Director
• D. Scott Davis,
  Independent Director
• A. Eugene Washington,
  Independent Director
• Jennifer Doudna,
  Independent Director
• Mark McClellan,
  Independent Director
• Ian Davis,
  Independent Director
• Marillyn Hewson,
  Independent Director
• Mark Weinberger,
  Independent Director
• Hubert Joly,
  Independent Director
• Christopher DelOrefice,
  Vice President, Investor Relations
• Kathryn Wengel,
  Executive Vice President, Chief Global Supply Chain Officer
• Michael Sneed,
  Executive Vice President - Global Corporate Affairs and Chief Communication Officer
• Thibaut Mongon,
  Executive Vice President, Worldwide Chairman, Consumer
• Ashley McEvoy,
  Executive Vice President - Worldwide Chairman, Medical Devices
• Dr. Guy J. Lebeau M.D.,
  Group Chairman of MD&D Bus. - EMEA
• Dr. Peter M. Fasolo Ph.D.,
  Exec. VP & Chief HR Officer
• Michael H. Ullmann,
  Exec. VP & Gen. Counsel
• Jessica Moore,
  VP of Investor Relations
• Ashley Watson,
  Chief Compliance Officer
• James Swanson,
  Exec. VP & Global CIO
• Robert J. Decker Jr.,
  Controller & Chief Accounting Officer
• James Cullen,
  Director
• Stephen J Cosgrove,
  
• Leo F Mullin,
  Director
• Michael M E Johns,
  Director
• Robert J Decker,
  VP Corporate Controller
• Elizabeth Forminard,
  Executive VP, General Counsel
• Ronald A Kapusta,
  Controller, CAO
• Susan L Lindquist,
  Director
• Gary J Pruden,
  Exec VP, WW Chair, Med Devices
• William D Perez,
  Director
• Jorge S. Mesquita,
  Exec VP, WW Chair, Consumer
• Dominic J Caruso,
  Chief Financial Officer
• Timothy Schmid,
  EVP, WW Chair, MedTech
• Mary Sue Coleman,
  Director
• David Satcher,
  Director
• William C Weldon,
  Chairman/CEO
• Arnold G Langbo,
  Director
• Russell C Deyo,
  Vice President, Administration
• Kaye I Foster Cheek,
  VP, Human Resources
• Colleen A Goggins,
  Member, Executive Committee
• Sherilyn S Mc Coy,
  Member, Executive Committee
• Donald M Jr. Casey,
  Member, Executive Committee
• Nicholas J Valeriani,
  Vice President,Human Resources
• Christine A Poon,
  Executive Committee Member
• Joseph C Scodari,
  Executive Committee Member
• Steven Reinemund,
  Director
• Ann Dibble Jordan,
  Director
• Robert J Darretta,
  Member, Executive Committee
• Per A Peterson,
  Executive Committee Member
• Michael J Dormer,
  Member, Executive Committee
• Joann Heffernan Heisen,
  Member, Executive Committee
• Gerard N Burrow,
  Director
• Henry B Schacht,
  Director
• M Judah Folkman,
  Director
• Roger S Fine,
  Vice President General Counsel
• James T Lenehan,
  Vice Chairman
• Brian D Perkins,
  Executive Committee Member
• Robert N Wilson,
  
• Nadja West,
  Director
• Vanessa Broadhurst,
  EVP, Global Corp Affairs
• Mathai Mammen,
  EVP, Pharm, R&D
• William Hait,
  EVP, Chief EI and Med Officer
• Darius Adamczyk,
  Director
• James D. Swanson,
  EVP, CIO
• John C Reed,
  EVP, Innovative Medicine, R&D
• Paula A Johnson,
  Director
• Eugene A. Woods,
  Director